320 related articles for article (PubMed ID: 31212653)
1. PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
Manjunath Y; Upparahalli SV; Avella DM; Deroche CB; Kimchi ET; Staveley-O'Carroll KF; Smith CJ; Li G; Kaifi JT
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212653
[TBL] [Abstract][Full Text] [Related]
2. Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancer.
Jiang J; Mo W; Lian X; Cao D; Cheng H; Wang H
Exp Ther Med; 2024 Jul; 28(1):294. PubMed ID: 38827467
[TBL] [Abstract][Full Text] [Related]
3. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
[TBL] [Abstract][Full Text] [Related]
4. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
[TBL] [Abstract][Full Text] [Related]
5. Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients.
Asante DB; Morici M; Mohan GRKA; Acheampong E; Spencer I; Lin W; van Miert P; Gibson S; Beasley AB; Ziman M; Calapre L; Meniawy TM; Gray ES
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944844
[TBL] [Abstract][Full Text] [Related]
6. Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.
Janning M; Kobus F; Babayan A; Wikman H; Velthaus JL; Bergmann S; Schatz S; Falk M; Berger LA; Böttcher LM; Päsler S; Gorges TM; O'Flaherty L; Hille C; Joosse SA; Simon R; Tiemann M; Bokemeyer C; Reck M; Riethdorf S; Pantel K; Loges S
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212989
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system
Raimondi C; Carpino G; Nicolazzo C; Gradilone A; Gianni W; Gelibter A; Gaudio E; Cortesi E; Gazzaniga P
Oncoimmunology; 2017; 6(12):e1315488. PubMed ID: 29209560
[TBL] [Abstract][Full Text] [Related]
10. Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.
Acheampong E; Morici M; Abed A; Bowyer S; Asante DB; Lin W; Millward M; Gray ES; Beasley AB
J Cancer Res Clin Oncol; 2023 May; 149(5):1941-1950. PubMed ID: 35896898
[TBL] [Abstract][Full Text] [Related]
11. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
[TBL] [Abstract][Full Text] [Related]
12. PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC).
Pantazaka E; Ntzifa A; Roumeliotou A; Lianidou E; Georgoulias V; Kotsakis A; Kallergi G
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009440
[TBL] [Abstract][Full Text] [Related]
13. Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients.
Ntzifa A; Strati A; Kallergi G; Kotsakis A; Georgoulias V; Lianidou E
Sci Rep; 2021 Jan; 11(1):2313. PubMed ID: 33504904
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.
Kallergi G; Vetsika EK; Aggouraki D; Lagoudaki E; Koutsopoulos A; Koinis F; Katsarlinos P; Trypaki M; Messaritakis I; Stournaras C; Georgoulias V; Kotsakis A
Ther Adv Med Oncol; 2018; 10():1758834017750121. PubMed ID: 29383038
[TBL] [Abstract][Full Text] [Related]
15. Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I-III Non-small Cell Lung Cancer Patients.
Dong J; Zhu D; Tang X; Qiu X; Lu D; Li B; Lin D; Zhou Q
Front Oncol; 2019; 9():1139. PubMed ID: 31737568
[No Abstract] [Full Text] [Related]
16. Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients.
Yang L; Yan X; Chen J; Zhan Q; Hua Y; Xu S; Li Z; Wang Z; Dong Y; Zuo D; Xue M; Tang Y; Herschman HR; Lu S; Shi Q; Wei W
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836566
[TBL] [Abstract][Full Text] [Related]
17. Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence.
Garcia J; Barthelemy D; Geiguer F; Ballandier J; Li KW; Aurel JP; Le Breton F; Rodriguez-Lafrasse C; Manship B; Couraud S; Payen L
J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475991
[TBL] [Abstract][Full Text] [Related]
18. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
Bian J; Yan K; Liu N; Xu X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
[TBL] [Abstract][Full Text] [Related]
19. Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients.
Katsarou SD; Messaritakis I; Voumvouraki A; Kakavogiannis S; Κotsakis A; Alkahtani S; Stournaras C; Martin SS; Georgoulias V; Kallergi G
J Pers Med; 2022 Jan; 12(2):. PubMed ID: 35207643
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
